RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Cancer Treatment Reviews

Volumn 50, Issue , 2016, Pages 35-47

  Barata, Pedro ^a   Sood, Anil K ^b   Hong, David S ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

Antisense oligonucleotides; Cancer clinical trials; miRNA; RNA therapeutics; siRNA

Indexed keywords

AEG 35156; ANTISENSE OLIGONUCLEOTIDE; APATORSEN; APRINOCARSEN; CAPECITABINE; CARBOPLATIN; CGP 69846A; CISPLATIN; CUSTIRSEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GATAPARSEN; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 2040; IMETELSTAT; INTERFERON; IRINOTECAN; ISIS 2503; MICRORNA; OBLIMERSEN; OXALIPLATIN; PACLITAXEL; PREDNISONE; SMALL INTERFERING RNA; TRABEDERSEN; TRASTUZUMAB; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANASARCA; ANEMIA; ANOREXIA; ASCITES; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN HEMORRHAGE; CANCER THERAPY; CHILL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIARRHEA; DRUG FATALITY; EDEMA; FATIGUE; FEMALE GENITAL TRACT CANCER; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GLIOMA; HAIR LOSS; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CANCER; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LUNG EMBOLISM; LYMPHATIC LEUKEMIA; MELANOMA; MERKEL CELL TUMOR; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN TARGETING; REVIEW; RNAI THERAPEUTICS; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR; CLINICAL TRIAL (TOPIC); NEOPLASMS; PROCEDURES;

CLINICAL TRIALS AS TOPIC; HUMANS; MICRORNAS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84986552471     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.08.004     Document Type: Review

References (171)

1. [1] Wu, S.Y., Lopez-Berestein, G., Calin, G.A., Sood, A.K., RNAi therapies: drugging the undruggable.Sci Transl Med., 6, 2014, 240ps247.
2. [2] Burnett, J.C., Rossi, J.J., RNA-based therapeutics – current progress and future prospects. Chem Biol 19 (2012), 60–71.
3. [3] Kjems, J., Howard, K.A., Oligonucleotide delivery to the lung: waiting to inhale. Mol Ther Nucleic Acids, 1, 2012, e1.
4. [4] Goodchild, J., Therapeutic oligonucleotides. Methods Mol Biol 764 (2011), 1–15.
5. [5] Lee, R.C., Feinbaum, R.L., Ambros, V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
6. [6] Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001), 494–498.
7. [7] Agrawal, N., Dasaradhi, P.V.N., Mohmmed, A., Malhotra, P., Bhatnagar, R.K., Mukherjee, S.K., RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67 (2003), 657–685.
8. [8] Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998), 806–811.
9. [9] Kole, R., Krainer, A.R., Altman, S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discovery 11 (2012), 125–140.
10. [10] Mattick, J.S., Makunin, I.V., Non-coding RNA. Hum Mol Genet, 2006, R17–R29 15 Spec No 1.
11. [11] Lam, J.K., Chow, M.Y., Zhang, Y., Leung, S.W., SiRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids, 4, 2015, e252.
12. [12] Behlke, M.A., Progress towards in vivo use of siRNAs. Mol Ther 13 (2006), 644–670.
13. [13] Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15 (2014), 509–524.
14. [14] Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., Croce, C.M., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101 (2004), 2999–3004.
15. [15] Bader, A.G., Brown, D., Winkler, M., The promise of microRNA replacement therapy. Cancer Res 70 (2010), 7027–7030.
16. [16] Crooke, S.T., Vickers, T., Lima, W., Wu, H., Mechanisms of antisense drug action, an introduction. 2007, CRC Press, Boca Raton.
17. [17] Guo, W., Chen, W., Yu, W., Huang, W., Deng, W., Small interfering RNA-based molecular therapy of cancers. Chin J Cancer 32 (2013), 488–493.
18. [18] Cullen, L.M., Arndt, G.M., Genome-wide screening for gene function using RNAi in mammalian cells. Immunol Cell Biol 83 (2005), 217–223.
19. [19] Berns, K., Hijmans, E.M., Mullenders, J., Brummelkamp, T.R., Velds, A., Heimerikx, M., Kerkhoven, R.M., Madiredjo, M., Nijkamp, W., Weigelt, B., Agami, R., Ge, W., Cavet, G., Linsley, P.S., Beijersbergen, R.L., Bernards, R., A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004), 431–437.
20. [20] Mercer, J., Snijder, B., Sacher, R., Burkard, C., Bleck, C.K., Stahlberg, H., Pelkmans, L., Helenius, A., RNAi screening reveals proteasome- and Cullin3-dependent stages in vaccinia virus infection. Cell Rep 2 (2012), 1036–1047.
21. [21] Wu, S.Y., Yang, X., Gharpure, K.M., Hatakeyama, H., Egli, M., McGuire, M.H., Nagaraja, A.S., Miyake, T.M., Rupaimoole, R., Pecot, C.V., Taylor, M., Pradeep, S., Sierant, M., Rodriguez-Aguayo, C., Choi, H.J., Previs, R.A., Armaiz-Pena, G.N., Huang, L., Martinez, C., Hassell, T., Ivan, C., Sehgal, V., Singhania, R., Han, H.-D., Su, C., Kim, J.H., Dalton, H.J., Kovvali, C., Keyomarsi, K., McMillan, N.A.J., Overwijk, W.W., Liu, J., Lee, J.-S., Baggerly, K.A., Lopez-Berestein, G., Ram, P.T., Nawrot, B., Sood, A.K., 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun, 5, 2014.
22. [22] Wang, J., Lu, Z., Wientjes, M.G., Au, J.L., Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12 (2010), 492–503.
23. [23] Bakhtiyari, S., Haghani, K., Basati, G., Karimfar, M.H., SiRNA therapeutics in the treatment of diseases. Ther Delivery 4 (2013), 45–57.
24. [24] Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat Mater 12 (2013), 967–977.
25. [25] Ramanathan, R.K., Hamburg, S.I., Borad, M.J., Seetharam, M., Kundranda, M.N., Lee, P., Fredlund, P., Gilbert, M., Mast, C., Semple, S.C., A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. Cancer Res, 2013 Amer Assoc cancer research 615 Chestnut ST, 17th Floor, Philadelphia, PA 19106-4404, USA.
26. [26] Cervantes, A., Alsina, M., Tabernero, J., Infante, J., LoRusso, P., Shapiro, G., Paz-Ares, L., Falzone, R., Hill, J., Cehelsky, J., Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol, 2011 Amer Soc Clinical Oncology 2318 Mill Road, STE 800, Alexandria, VA 22314, USA.
27. [27] Zuckerman, J.E., Gritli, I., Tolcher, A., Heidel, J.D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M.E., Yen, Y., Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA 111 (2014), 11449–11454.
28. [28] Golan, T., Khvalevsky, E.Z., Hubert, A., Gabai, R.M., Hen, N., Segal, A., Domb, A., Harari, G., David, E.B., Raskin, S., Goldes, Y., Goldin, E., Eliakim, R., Lahav, M., Kopleman, Y., Dancour, A., Shemi, A., Galun, E., RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 6 (2015), 24560–24570.
29. [29] Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., Drevs, J., First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 32 (2014), 4141–4148.
30. [30] Schultheis, B., A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma. J Clin Oncol, 34, 2016.
31. [31] Rolle, K., Nowak, S., Wyszko, E., Nowak, M., Zukiel, R., Piestrzeniewicz, R., Gawronska, I., Barciszewska, M.Z., Barciszewski, J., Promising human brain tumors therapy with interference RNA intervention IRNAi. Cancer Biol Ther 9 (2010), 396–406.
32. [32] Tolcher AW, Papadopoulos KP, Patnaik A, Rasco DW, Martinez D, Wood DL, Fielman B, Sharma M, Janisch LA, Brown BD. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC. In: A phase I study in patients with advanced solid tumors, ASCO Annual Meeting Proceedings; 2015, p. 11006.
33. [33] Kutter, C., Svoboda, P., MiRNA, siRNA, piRNA: Knowns of the unknown. RNA Biol 5 (2008), 181–188.
34. [34] He, L., Hannon, G.J., MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5 (2004), 522–531.
35. [35] Reddy, K.B., MicroRNA (miRNA) in cancer. Cancer Cell Int, 15, 2015, 38.
36. [36] Zavala, V., Perez-Moreno, E., Tapia, T., Camus, M., Carvallo, P., MiR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival. Cancer Biomarkers 16 (2016), 99–107.
37. [37] Sun, C., Li, S., Yang, C., Xi, Y., Wang, L., Zhang, F., Li, D., MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochem Biophys Res Commun, 2016.
38. [38] Gill, B.S., Alex, J.M., Navgeet, Kumar, S., Missing link between microRNA and prostate cancer. Tumour Biol, 2016.
39. [39] Fjose, A., Drivenes, O., RNAi and microRNAs: from animal models to disease therapy. Birth Defects Res C Embryo Today 78 (2006), 150–171.
40. [40] Aqeilan, R.I., Calin, G.A., Croce, C.M., MiR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17 (2010), 215–220.
41. [41] Misso, G., Di Martino, M.T., De Rosa, G., Farooqi, A.A., Lombardi, A., Campani, V., Zarone, M.R., Gulla, A., Tagliaferri, P., Tassone, P., Caraglia, M., Mir-34: a new weapon against cancer?. Mol Ther Nucleic Acids, 3, 2014, e194.
42. [42] Rupaimoole, R., Calin, G.A., Lopez-Berestein, G., Sood, A.K., MiRNA deregulation in cancer cells and the tumor microenvironment. Cancer discovery 6 (2016), 235–246.
43. [43] Nishimura, M., Jung, E.J., Shah, M.Y., Lu, C., Spizzo, R., Shimizu, M., Han, H.D., Ivan, C., Rossi, S., Zhang, X., Nicoloso, M.S., Wu, S.Y., Almeida, M.I., Bottsford-Miller, J., Pecot, C.V., Zand, B., Matsuo, K., Shahzad, M.M., Jennings, N.B., Rodriguez-Aguayo, C., Lopez-Berestein, G., Sood, A.K., Calin, G.A., Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery 3 (2013), 1302–1315.
44. [44] Moreno, P.M., Pego, A.P., Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem, 2, 2014, 87.
45. [45] Sharma, V.K., Sharma, R.K., Singh, S.K., Antisense oligonucleotides: modifications and clinical trials. MedChemComm 5 (2014), 1454–1471.
46. [46] Yu, R.Z., Grundy, J.S., Geary, R.S., Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9 (2013), 169–182.
47. [47] Watts, J.K., Deleavey, G.F., Damha, M.J., Chemically modified siRNA: tools and applications. Drug Discovery Today 13 (2008), 842–855.
48. [48] Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J.S., Broder, S., Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 84 (1987), 7706–7710.
49. [49] Agrawal, S., Mayrand, S.H., Zamecnik, P.C., Pederson, T., Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci USA 87 (1990), 1401–1405.
50. [50] Mansoor, M., Melendez, A.J., Advances in antisense oligonucleotide development for target identification validation, and as novel therapeutics. Gene Regul Syst Biol 2 (2008), 275–295.
51. [51] Mahadevan, D., Chalasani, P., Rensvold, D., Kurtin, S., Pretzinger, C., Jolivet, J., Ramanathan, R.K., Von Hoff, D.D., Weiss, G.J., Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol 36 (2013), 239–243.
52. [52] Raab, R., Sparano, J.A., Ocean, A.J., Christos, P., Ramirez, M., Vinciguerra, V., Kaubisch, A., A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Am J Clin Oncol 33 (2010), 61–65.
53. [53] Mita, M.M., Ochoa, L., Rowinsky, E.K., Kuhn, J., Schwartz, G., Hammond, L.A., Patnaik, A., Yeh, I.T., Izbicka, E., Berg, K., Tolcher, A.W., A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 17 (2006), 313–321.
54. [54] Shah, M.H., Varker, K.A., Collamore, M., Zwiebel, J.A., Coit, D., Kelsen, D., Chung, K.Y., G3139 (Genasense) in patients with advanced merkel cell carcinoma. Am J Clin Oncol 32 (2009), 174–179.
55. [55] Cripps, M.C., Figueredo, A.T., Oza, A.M., Taylor, M.J., Fields, A.L., Holmlund, J.T., McIntosh, L.W., Geary, R.S., Eisenhauer, E.A., Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 8 (2002), 2188–2192.
56. [56] Alberts, S.R., Schroeder, M., Erlichman, C., Steen, P.D., Foster, N.R., Moore, D.F. Jr., Rowland, K.M. Jr., Nair, S., Tschetter, L.K., Fitch, T.R., Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 22 (2004), 4944–4950.
57. [57] Burris, H.A. 3rd, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., Nelson, R., Dorr, F.A., Stephens, C.D., Von Hoff, D.D., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997), 2403–2413.
58. [58] Hong, D.S., Kurzrock, R., Oh, Y., Wheler, J., Naing, A., Brail, L., Callies, S., Andre, V., Kadam, S.K., Nasir, A., Holzer, T.R., Meric-Bernstam, F., Fishman, M., Simon, G., A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17 (2011), 6582–6591.
59. [59] Chi KN, Sweeney C, Jacobs C, Stewart PS, Hahn NM. The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA). In: ASCO Annual Meeting Proceedings; 2013, p. TPS5101.
60. [60] Bellmunt, J., Eigl, B., Senkus-Konefka, E., First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: the International Borealis-1 trial. J Clin Oncol, 33, 2015.
61. [61] Tolcher, A.W., Kuhn, J., Schwartz, G., Patnaik, A., Hammond, L.A., Thompson, I., Fingert, H., Bushnell, D., Malik, S., Kreisberg, J., Izbicka, E., Smetzer, L., Rowinsky, E.K., A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10 (2004), 5048–5057.
62. [62] Sternberg, C.N., Dumez, H., Van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabro, F., Collette, L., Lacombe, D., Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20 (2009), 1264–1269.
63. [63] Margolin, K., Synold, T.W., Lara, P., Frankel, P., Lacey, S.F., Quinn, D.I., Baratta, T., Dutcher, J.P., Xi, B., Diamond, D.J., Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol 133 (2007), 705–711.
64. [64] Moulder, S.L., Symmans, W.F., Booser, D.J., Madden, T.L., Lipsanen, C., Yuan, L., Brewster, A.M., Cristofanilli, M., Hunt, K.K., Buchholz, T.A., Zwiebel, J., Valero, V., Hortobagyi, G.N., Esteva, F.J., Phase I/II study of G3139 (bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14 (2008), 7909–7916.
65. [65] Chi, K.N., Gleave, M.E., Klasa, R., Murray, N., Bryce, C., Lopes de Menezes, D.E., D'Aloisio, S., Tolcher, A.W., A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7 (2001), 3920–3927.
66. [66] Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., Wood, L., Pollak, M., Berry, S., Lattouf, J.B., Mukherjee, S.D., Gleave, M., Winquist, E., Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17 (2011), 5765–5773.
67. [67] Chia, S., Dent, S., Ellard, S., Ellis, P.M., Vandenberg, T., Gelmon, K., Powers, J., Walsh, W., Seymour, L., Eisenhauer, E.A., Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 15 (2009), 708–713.
68. [68] Chi, K.N., Eisenhauer, E., Fazli, L., Jones, E.C., Goldenberg, S.L., Powers, J., Tu, D., Gleave, M.E., A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2’-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005), 1287–1296.
69. [69] Chi KN, Higano CS, Blumenstein BA, Reeves JA, Feyerabend S, Gravis G, Ferrero J-M, Jacobs C, De Bono JS, Investigators S. Phase III SYNERGY trial: docetaxel+/-custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. In: ASCO Annual Meeting Proceedings; 2015, p. 5009.
70. [70] Miller, K., Steding, C., Prasad, N., Rojas, L., Herbert, B., Abstract P5-18-13: inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+ breast cancer. Cancer Res 72 (2012), P5-18-13–P15-18-13.
71. [71] Kozloff, M., Sledge, G., Benedetti, F., Starr, A., Wallace, J., Stuart, M., Gruver, D., Miller, K., Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). J Clin Oncol, 28, 2010, 15s.
72. [72] Wiechno, P., Somer, B.G., Mellado, B., Chlosta, P.L., Cervera Grau, J.M., Castellano, D., Reuter, C., Stockle, M., Kamradt, J., Pikiel, J., Duran, I., Wedel, S., Callies, S., Andre, V., Hurt, K., Brown, J., Lahn, M., Heinrich, B., A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol 65 (2014), 516–520.
73. [73] Tolcher, A.W., Reyno, L., Venner, P.M., Ernst, S.D., Moore, M., Geary, R.S., Chi, K., Hall, S., Walsh, W., Dorr, A., Eisenhauer, E., A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8 (2002), 2530–2535.
74. [74] Tagawa, S.G.S.M.G.B.E., Archexin, a novel AKT-1-specific inhibitor for the treatment of metastatic renal cancer: preliminary phase I data. J Clin Oncol, 34(Suppl. 2S), 2016 Abstr 550.
75. [75] Bianchini, D., Omlin, A., Pezaro, C., Lorente, D., Ferraldeschi, R., Mukherji, D., Crespo, M., Figueiredo, I., Miranda, S., Riisnaes, R., Zivi, A., Buchbinder, A., Rathkopf, D.E., Attard, G., Scher, H.I., de Bono, J., Danila, D.C., First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 109 (2013), 2579–2586.
76. [76] Stadler, W.M., Desai, A.A., Quinn, D.I., Bukowski, R., Poiesz, B., Kardinal, C.G., Lewis, N., Makalinao, A., Murray, P., Torti, F.M., A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol 61 (2008), 689–694.
77. [77] Sridhar, S.S., Canil, C.M., Chi, K.N., Hotte, S.J., Ernst, S., Wang, L., Chen, E.X., Juhasz, A., Yen, Y., Murray, P., Zwiebel, J.A., Moore, M.J., A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol 67 (2011), 927–933.
78. [78] Rudin, C.M., Salgia, R., Wang, X., Hodgson, L.D., Masters, G.A., Green, M., Vokes, E.E., Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26 (2008), 870–876.
79. [79] Ott, P.A., Chang, J., Madden, K., Kannan, R., Muren, C., Escano, C., Cheng, X., Shao, Y., Mendoza, S., Gandhi, A., Liebes, L., Pavlick, A.C., Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol 71 (2013), 183–191.
80. [80] Bedikian, A.Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A.C., DeConti, R., Hersh, E.M., Hersey, P., Kirkwood, J.M., Haluska, F.G., Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006), 4738–4745.
81. [81] Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., Pehamberger, H., Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000), 1728–1733.
82. [82] Laskin, J.J., Nicholas, G., Lee, C., Gitlitz, B., Vincent, M., Cormier, Y., Stephenson, J., Ung, Y., Sanborn, R., Pressnail, B., Nugent, F., Nemunaitis, J., Gleave, M.E., Murray, N., Hao, D., Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 7 (2012), 579–586.
83. [83] Chiappori, A.A., Kolevska, T., Spigel, D.R., Hager, S., Rarick, M., Gadgeel, S., Blais, N., Von Pawel, J., Hart, L., Reck, M., Bassett, E., Burington, B., Schiller, J.H., A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol 26 (2015), 354–362.
84. [84] Natale, R., Blackhall, F., Kowalski, D., Ramlau, R., Bepler, G., Grossi, F., Lerchenmuller, C., Pinder-Schenck, M., Mezger, J., Danson, S., Gadgeel, S.M., Summers, Y., Callies, S., Andre, V., Das, M., Lahn, M., Talbot, D., Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J Thorac Oncol 9 (2014), 1704–1708.
85. [85] Ritch, P., Rudin, C.M., Bitran, J.D., Edelman, M.J., Makalinao, A., Irwin, D., Lilenbaum, R., Peterson, P., John, W.J., Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 52 (2006), 173–180.
86. [86] Paz-Ares, L., Douillard, J.Y., Koralewski, P., Manegold, C., Smit, E.F., Reyes, J.M., Chang, G.C., John, W.J., Peterson, P.M., Obasaju, C.K., Lahn, M., Gandara, D.R., Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 24 (2006), 1428–1434.
87. [87] Villalona-Calero, M.A., Ritch, P., Figueroa, J.A., Otterson, G.A., Belt, R., Dow, E., George, S., Leonardo, J., McCachren, S., Miller, G.L., Modiano, M., Valdivieso, M., Geary, R., Oliver, J.W., Holmlund, J., A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 10 (2004), 6086–6093.
88. [88] Vansteenkiste, J., Canon, J.L., Riska, H., Pirker, R., Peterson, P., John, W., Mali, P., Lahn, M., Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs 23 (2005), 263–269.
89. [89] Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., Ritch, P., Harker, G., Ahmed, F., Jones, C., Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. Clin. Cancer Res., 2001 Amer Assoc Cancer Research PO Box 11806, Birmingham, AL 35202 USA; 3681S–3681S.
90. [90] Raju, R., Lynch, T.J., Lind, M., Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc Am Soc Clin Oncol, 22, 2003, 623.
91. [91] Grossman, S.A., Alavi, J.B., Supko, J.G., Carson, K.A., Priet, R., Dorr, F.A., Grundy, J.S., Holmlund, J.T., Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol 7 (2005), 32–40.
92. [92] Coudert, B., Anthoney, A., Fiedler, W., Droz, J.P., Dieras, V., Borner, M., Smyth, J.F., Morant, R., de Vries, M.J., Roelvink, M., Fumoleau, P., Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Euro J Cancer, 37, 2001, 2194.
93. [93] Bogdahn U, Hau P, Brawanski A, Schlaier J, Mehdorn M, Wurm G, Pichler J, Kunst M, Stauder G, Schlingensiepen K-H. Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-{beta} 2 specific antisense oligonucleotide AP 12009. In: ASCO Annual Meeting Proceedings; 2004, p. 1514.
94. [94] Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N.K., Mahapatra, A.K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Poverennova, I., Zaaroor, M., Jachimczak, P., Ludwig, S., Schmaus, S., Heinrichs, H., Schlingensiepen, K.H., Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13 (2011), 132–142.
95. [95] Oettle, H., Hilbig, A., Seufferlein, T., Tsianakas, A., Luger, T., Schmid, R., von Wichert, G., Endlicher, E., Garbe, C., Kaehler, K., Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. J. Clin. Oncol., 2011 Amer Soc Clinical Oncology 2318 Mill Road, STE 800, Alexandria, VA 22314, USA.
96. [96] Lynch, T., Raju, R., Lind, M., Riviere, A., Gatzemeier, U., Drorr, A., Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc Am Soc Clin Oncol, 2003, 623.
97. [97] Rudin, C.M., Otterson, G.A., Mauer, A.M., Villalona-Calero, M.A., Tomek, R., Prange, B., George, C.M., Szeto, L., Vokes, E.E., A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13 (2002), 539–545.
98. [98] Levine, A.M., Tulpule, A., Quinn, D.I., Gorospe, G. 3rd, Smith, D.L., Hornor, L., Boswell, W.D., Espina, B.M., Groshen, S.G., Masood, R., Gill, P.S., Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 24 (2006), 1712–1719.
99. [99] Bedikian, A.Y., Garbe, C., Conry, R., Lebbe, C., Grob, J.J., Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: ’The AGENDA trial. Melanoma Res 24 (2014), 237–243.
100. [100] Marcucci, G., Stock, W., Dai, G., Klisovic, R.B., Liu, S., Klisovic, M.I., Blum, W., Kefauver, C., Sher, D.A., Green, M., Moran, M., Maharry, K., Novick, S., Bloomfield, C.D., Zwiebel, J.A., Larson, R.A., Grever, M.R., Chan, K.K., Byrd, J.C., Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23 (2005), 3404–3411.
101. [101] Chanan-Khan, A.A., Munshi, N.C., Hussein, M.A., Elias, L., Benedetti, F., Smith, J., Khor, S.-P., Huff, C.A., Results of a phase I study of GRN163L, a direct inhibitor of telomerase, in patients with relapsed and refractory multiple myeloma (MM). Blood, 2008 Amer Soc Hematology 1900 M Street. NW Suite 200, Washington, DC 20036, USA; 1263–1263.
102. [102] Rao, S., Watkins, D., Cunningham, D., Dunlop, D., Johnson, P., Selby, P., Hancock, B.W., Fegan, C., Culligan, D., Schey, S., Morris, T.C., Lissitchkov, T., Oliver, J.W., Holmlund, J.T., Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol 15 (2004), 1413–1418.
103. [103] Erba, H.P., Sayar, H., Juckett, M., Lahn, M., Andre, V., Callies, S., Schmidt, S., Kadam, S., Brandt, J.T., Van Bockstaele, D., Andreeff, M., Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs 31 (2013), 1023–1034.
104. [104] Schimmer, A.D., Estey, E.H., Borthakur, G., Carter, B.Z., Schiller, G.J., Tallman, M.S., Altman, J.K., Karp, J.E., Kassis, J., Hedley, D.W., Brandwein, J., Xu, W., Mak, D.H., LaCasse, E., Jacob, C., Morris, S.J., Jolivet, J., Andreeff, M., Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 27 (2009), 4741–4746.
105. [105] Cortes, J., Kantarjian, H., Ball, E.D., Dipersio, J., Kolitz, J.E., Fernandez, H.F., Goodman, M., Borthakur, G., Baer, M.R., Wetzler, M., Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118 (2012), 418–427.
106. [106] Kantarjian, H.M., Ravandi, F., Borthakur, G., Garcia-Manero, G., Andreeff, M., Jabbour, E., Konopleva, M., O'Brien, S., Quintas-Cardama, A., Somer, B.G., Tari, A., Verstovsek, S., Wierda, W.G., Cortes, J.E., Safety, pharmacokinetics, and Efficacy Of BP-100-1.01 (liposomal Grb-2 antisense oligonucleotide) in patients with refractory or relapsed acute myeloid leukemia (AML), philadelphia chromosome positive chronic myelogenous leukemia (CML), acute lymphoblast. Blood, 122, 2013, 2679.
107. [107] Klisovic, R.B., Blum, W., Liu, Z., Xie, Z., Kefauver, C., Huynh, L., Zwiebel, J.A., Devine, S.M., Byrd, J.C., Grever, M.R., Chan, K.K., Marcucci, G., Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 55 (2014), 1332–1336.
108. [108] Bishop, M.R., Iversen, P.L., Bayever, E., Sharp, J.G., Greiner, T.C., Copple, B.L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J.O., Kessinger, A., Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14 (1996), 1320–1326.
109. [109] Tanioka, M., Nokihara, H., Yamamoto, N., Yamada, Y., Yamada, K., Goto, Y., Fujimoto, T., Sekiguchi, R., Uenaka, K., Callies, S., Tamura, T., Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 68 (2011), 505–511.
110. [110] Schimmer, A.D., Herr, W., Hanel, M., Borthakur, G., Frankel, A., Horst, H.A., Martin, S., Kassis, J., Desjardins, P., Seiter, K., Fiedler, W., Noppeney, R., Giagounidis, A., Jacob, C., Jolivet, J., Tallman, M.S., Koschmieder, S., Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma, Myeloma Leuk 11 (2011), 433–438.
111. [111] Klisovic B, Blum W, Chen P, Xie Z, Liu S, Walker A, Devine S, Garzon R, Byrd J, Wetzler M. A phase II study Of GTI-2040, an antisense to ribonucleotide reductase in combination with high-dose cytarabine in relapsed or refractory acute myeloid leukemia, haematologica-the hematology journal, ferrata storti foundation via Giuseppe Belli 4, 27100 Pavia, Italy; 2010, p. 27–27.
112. [112] Moore, J., Seiter, K., Kolitz, J., Stock, W., Giles, F., Kalaycio, M., Zenk, D., Marcucci, G., A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 30 (2006), 777–783.
113. [113] Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz J, Thakuri M, Carter T, Stuart R, Larson R. A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. In: ASCO Annual Meeting Proceedings; 2007, p. 7012.
114. [114] Chanan-Khan, A.A., Niesvizky, R., Hohl, R.J., Zimmerman, T.M., Christiansen, N.P., Schiller, G.J., Callander, N., Lister, J., Oken, M., Jagannath, S., Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 50 (2009), 559–565.
115. [115] Wetzler, M., Donohue, K.A., Odenike, O.M., Feldman, E.J., Hurd, D.D., Stone, R.M., Westerfelt, P., Bloomfield, C.D., Larson, R.A., Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – cancer and leukemia group B study 10107. Leuk Lymphoma 49 (2008), 1274–1278.
116. [116] Tilly H, Coiffier B, Michallet A, Radford J, Geisler C, Gadeberg O, Dalseg A, Steenken E, Worsaae Dalby L. Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukemia (CLL). In: ASCO Annual Meeting Proceedings; 2007, p. 7036.
117. [117] O'Brien, S., Moore, J.O., Boyd, T.E., Larratt, L.M., Skotnicki, A., Koziner, B., Chanan-Khan, A.A., Seymour, J.F., Bociek, R.G., Pavletic, S., Rai, K.R., Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25 (2007), 1114–1120.
118. [118] Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., di Stefano, F., Cotter, F.E., Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18 (2000), 1812–1823.
119. [119] Klasa, R.J., Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (Williston Park) 18 (2004), 25–31.
120. [120] Pro, B., Leber, B., Smith, M., Fayad, L., Romaguera, J., Hagemeister, F., Rodriguez, A., McLaughlin, P., Samaniego, F., Zwiebel, J., Lopez, A., Kwak, L., Younes, A., Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143 (2008), 355–360.
121. [121] Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., Lee, S.J., Yamashita, M., Hughes, S.G., Fayad, L., Piha-Paul, S., Nadella, M.V.P., Mohseni, M., Lawson, D., Reimer, C., Blakey, D.C., Xiao, X., Hsu, J, Revenko, A., Monia, B.P., MacLeod, A.R., AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Science translational medicine, 7, 2015 314ra185–314ra185.
122. [122] Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat Biotechnol 32 (2014), 40–51.
123. [123] Bennett, C.F., Efficiency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev 12 (2002), 215–224.
124. [124] Singh, J., Kaur, H., Kaushik, A., Peer, S., A review of antisense therapeutic interventions for molecular biological targets in various diseases. In. J Pharmacol 7 (2011), 294–315.
125. [125] Teoh, H.K., Chong, P.P., Abdullah, M., Sekawi, Z., Tan, G.C., Leong, C.F., Cheong, S.K., Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth. Leuk Res 40 (2016), 44–53.
126. [126] Geary, R.S., Norris, D., Yu, R., Bennett, C.F., Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87 (2015), 46–51.
127. [127] Jain, T., Papas, A., Jadhav, A., McBride, R., Saez, E., In situ electroporation of surface-bound siRNAs in microwell arrays(). Lab Chip 12 (2012), 939–947.
128. [128] Tomar, R.S., Matta, H., Chaudhary, P.M., Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 22 (2003), 5712–5715.
129. [129] Chen, M., Du, Q., Zhang, H.-Y., Wahlestedt, C., Liang, Z., Vector-based siRNA delivery strategies for high-throughput screening of novel target genes. J RNAi Gene Silencing 1 (2005), 5–11.
130. [130] Layek, B., Lipp, L., Singh, J., Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid. Int J Mol Sci 16 (2015), 28912–28930.
131. [131] Gabrielson, N.P., Lu, H., Yin, L., Kim, K.H., Cheng, J., A cell-penetrating helical polymer for siRNA delivery to mammalian cells. Mol Ther 20 (2012), 1599–1609.
132. [132] Biswas, S., Torchilin, V.P., Dendrimers for siRNA Delivery. Pharmaceuticals 6 (2013), 161–183.
133. [133] Pisano, M., Baldinu, P., Sini, M.C., Ascierto, P.A., Tanda, F., Palmieri, G., Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. Ann Oncol 19 (2008), 2092–2093.
134. [134] Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, M.S., Zhang, C.-Z., Wala, J., Mermel, C.H., Sougnez, C., Gabriel, S.B., Hernandez, B., Shen, H., Laird, P.W., Getz, G., Meyerson, M., Beroukhim, R., Pan-cancer patterns of somatic copy number alteration. Nat Genet 45 (2013), 1134–1140.
135. [135] Rao, D.D., Wang, Z., Senzer, N., Nemunaitis, J., RNA interference and personalized cancer therapy. Discovery Med 15 (2013), 101–110.
136. [136] Komarova, N.L., Wodarz, D., Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 102 (2005), 9714–9719.
137. [137] Dritschilo, A., Huang, C.H., Rudin, C.M., Marshall, J., Collins, B., Dul, J.L., Zhang, C., Kumar, D., Gokhale, P.C., Ahmad, A., Ahmad, I., Sherman, J.W., Kasid, U.N., Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 12 (2006), 1251–1259.
138. [138] Beg, M.S., Brenner, A., Sachdev, J., Ejadi, S., Borad, M., Kang, Y.-K., Lim, H., Kim, T., Bader, A., Stoudemire, J., Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. Mol Cancer Ther, 14, 2015, C43.
139. [139] van Zandwijk, N., Pavlakis, N., Kao, S., Clarke, S., Lee, A., Brahmbhatt, H., Macdiarmid, J., Pattison, S., Leslie, F., Huynh, Y., Linton, A., Reid, G., P1.02MesomiR 1: A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC). Ann Oncol, 26, 2015 ii16.
140. [140] Rudin, C.M., Marshall, J.L., Huang, C.H., Kindler, H.L., Zhang, C., Kumar, D., Gokhale, P.C., Steinberg, J., Wanaski, S., Kasid, U.N., Ratain, M.J., Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10 (2004), 7244–7251.
141. [141] Stevenson, J.P., Yao, K.S., Gallagher, M., Friedland, D., Mitchell, E.P., Cassella, A., Monia, B., Kwoh, T.J., Yu, R., Holmlund, J., Dorr, F.A., O'Dwyer, P.J., Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 17 (1999), 2227–2236.
142. [142] Rudin, C.M., Holmlund, J., Fleming, G.F., Mani, S., Stadler, W.M., Schumm, P., Monia, B.P., Johnston, J.F., Geary, R., Yu, R.Z., Kwoh, T.J., Dorr, F.A., Ratain, M.J., Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7 (2001), 1214–1220.
143. [143] Fidias, P., Pennell, N.A., Boral, A.L., Shapiro, G.I., Skarin, A.T., Eder, J.P. Jr., Kwoh, T.J., Geary, R.S., Johnson, B.E., Lynch, T.J., Supko, J.G., Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol 4 (2009), 1156–1162.
144. [144] Mani, S., Rudin, C.M., Kunkel, K., Holmlund, J.T., Geary, R.S., Kindler, H.L., Dorr, F.A., Ratain, M.J., Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 8 (2002), 1042–1048.
145. [145] Makarova-Rusher, O.V., Duffy, A.G., Ulahannan, S.V., Fioravanti, S., Walker, M., Raffeld, M., Compton, K., Lee, S., Tomita, Y., Trepel, J.B., Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: final results. J Clin Oncol, 2015 Amer Soc Clinical Oncology 2318 Mill Road, STE 800, Alexandria, VA 22314, USA.
146. [146] Leighl, N., Laurie, S., Chen, X., Ellis, P., Shepherd, F., Knox, J., Goss, G., Burkes, R., Pond, G., Dick, C., Yen, Y., Zwiebel, J., Moore, M., A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). A study of the PMH Phase II Consortium. J Thorac Oncol 4 (2009), 1163–1169.
147. [147] Desai, A.A., Schilsky, R.L., Young, A., Janisch, L., Stadler, W.M., Vogelzang, N.J., Cadden, S., Wright, J.A., Ratain, M.J., A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16 (2005), 958–965.
148. [148] Shibata, S.I., Doroshow, J.H., Frankel, P., Synold, T.W., Yen, Y., Gandara, D.R., Lenz, H.J., Chow, W.A., Leong, L.A., Lim, D., Margolin, K.A., Morgan, R.J., Somlo, G., Newman, E.M., Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol 64 (2009), 1149–1155.
149. [149] Adjei, A.A., Dy, G.K., Erlichman, C., Reid, J.M., Sloan, J.A., Pitot, H.C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Atherton, P.J., Watanabe, T., Geary, R.S., Holmlund, J., Dorr, F.A., A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 9 (2003), 115–123.
150. [150] Morris, M.J., Tong, W.P., Cordon-Cardo, C., Drobnjak, M., Kelly, W.K., Slovin, S.F., Terry, K.L., Siedlecki, K., Swanson, P., Rafi, M., DiPaola, R.S., Rosen, N., Scher, H.I., Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8 (2002), 679–683.
151. [151] Liu, G., Kolesar, J., McNeel, D.G., Leith, C., Schell, K., Eickhoff, J., Lee, F., Traynor, A., Marnocha, R., Alberti, D., Zwiebel, J., Wilding, G., A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res 14 (2008), 2732–2739.
152. [152] Galatin, P.S., Advani, R.H., Fisher, G.A., Francisco, B., Julian, T., Losa, R., Sierra, M.I., Sikic, B.I., Phase I trial of oblimersen (Genasense(R)) and gemcitabine in refractory and advanced malignancies. Invest New Drugs 29 (2011), 971–977.
153. [153] Rheingold, S.R., Hogarty, M.D., Blaney, S.M., Zwiebel, J.A., Sauk-Schubert, C., Chandula, R., Krailo, M.D., Adamson, P.C., Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol 25 (2007), 1512–1518.
154. [154] Hotte S, Yu E, Hirte H, Higano C, Gleave M, Chi K. Phase I trial of OGX-427, a 2’methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): final results. In: ASCO Annual Meeting Proceedings; 2010, p. 3077.
155. [155] Chi, K.N., Siu, L.L., Hirte, H., Hotte, S.J., Knox, J., Kollmansberger, C., Gleave, M., Guns, E., Powers, J., Walsh, W., Tu, D., Eisenhauer, E., A phase I study of OGX-011, a 2’-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14 (2008), 833–839.
156. [156] Chen, H., Ness, E., Marshall, J., Martin, R., Dvorchik, B., Rizvi, N., Marquis, J., Dahut, W., Hawkins, M., Phase I trial of a second generation oligonucleotide (GEM 231) targeted at type I protein kinase. A in patients with refractory solid tumors. Proc Am Soc Clin Oncol, 1999, 159a.
157. [157] Goel, S., Desai, K., Macapinlac, M., Wadler, S., Goldberg, G., Fields, A., Einstein, M., Volterra, F., Wong, B., Martin, R., Mani, S., A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers. Invest New Drugs 24 (2005), 125–134.
158. [158] Jolivet J, Dean E, Ward T, Denneny O, Jacob C, Goodege P, Dive C, Ranson M. A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. In: ASCO Annual Meeting Proceedings; 2008, p. 3541.
159. [159] Dean, E., Jodrell, D., Connolly, K., Danson, S., Jolivet, J., Durkin, J., Morris, S., Jowle, D., Ward, T., Cummings, J., Dickinson, G., Aarons, L., Lacasse, E., Robson, L., Dive, C., Ranson, M., Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 27 (2009), 1660–1666.
160. [160] Malik S, Hwang J. Marshall J, Ramzi P, Posey J, Ahn C, Lee Y. Phase I study of RX-0201 in patients with advanced or metastatic solid tumors. In: ASCO Annual Meeting Proceedings; 2006, p. 13102.
161. [161] Advani, R., Lum, B.L., Fisher, G.A., Halsey, J., Geary, R.S., Holmlund, J.T., Kwoh, T.J., Dorr, F.A., Sikic, B.I., A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs 23 (2005), 467–477.
162. [162] Cunningham, C.C., Holmlund, J.T., Schiller, J.H., Geary, R.S., Kwoh, T.J., Dorr, A., Nemunaitis, J., A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 6 (2000), 1626–1631.
163. [163] Thompson, P.A., Drissi, R., Muscal, J.A., Panditharatna, E., Fouladi, M., Ingle, A.M., Ahern, C.H., Reid, J.M., Lin, T., Weigel, B.J., Blaney, S.M., A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (Trans.) ADVL1112 Clin Cancer Res 19 (2013), 6578–6584.
164. [164] Marshall, J.L., Eisenberg, S.G., Johnson, M.D., Hanfelt, J., Dorr, F.A., El-Ashry, D., Oberst, M., Fuxman, Y., Holmlund, J., Malik, S., A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer 4 (2004), 268–274.
165. [165] Oza, A.M., Elit, L., Swenerton, K., Faught, W., Ghatage, P., Carey, M., McIntosh, L., Dorr, A., Holmlund, J.T., Eisenhauer, E., Phase II study of CGP 69846A (Trans.) ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116 Gynecol Oncol 89 (2003), 129–133.
166. [166] Klisovic, R.B., Blum, W., Wei, X., Liu, S., Liu, Z., Xie, Z., Vukosavljevic, T., Kefauver, C., Huynh, L., Pang, J., Zwiebel, J.A., Devine, S., Byrd, J.C., Grever, M.R., Chan, K., Marcucci, G., Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14 (2008), 3889–3895.
167. [167] Raetz, E.A., Morrison, D., Romanos-Sirakis, E., Gaynon, P., Sposto, R., Bhojwani, D., Bostrom, B.C., Brown, P., Eckroth, E., Cassar, J., Malvar, J., Buchbinder, A., Carroll, W.L., A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol 36 (2014), 458–463.
168. [168] O'Brien, S.M., Cunningham, C.C., Golenkov, A.K., Turkina, A.G., Novick, S.C., Rai, K.R., Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005), 7697–7702.
169. [169] Lanasa, M.C., Davis, P.H., Datto, M., Li, Z., Gockerman, J.P., Moore, J.O., DeCastro, C.M., Friedman, D.R., Diehl, L.F., Rehder, C., Cook, H., Daugherty, F.J., Matta, K.M., Weinberg, J.B., Rizzieri, D., Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma 53 (2012), 218–224.
170. [170] Leonard J. Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). In: Proc Am Soc Clin Oncol; 2003, pp. 227a.
171. [171] Badros, A.Z., Goloubeva, O., Rapoport, A.P., Ratterree, B., Gahres, N., Meisenberg, B., Takebe, N., Heyman, M., Zwiebel, J., Streicher, H., Gocke, C.D., Tomic, D., Flaws, J.A., Zhang, B., Fenton, R.G., Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23 (2005), 4089–4099.